Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

WGS

GeneDx Holdings Corp

Apr 26 • 04:00PM ET

11.08

Dollar change -0.09
Percentage change -0.81	%

Healthcare • Health Information Services • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF AVSC DFAU

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-7.51	Insider Own	37.76%	Shs Outstand	25.98M	Perf Week	14.94%
Market Cap	288.63M	Forward P/E	-	EPS next Y	-1.42	Insider Trans	-7.16%	Shs Float	16.22M	Perf Month	17.12%
Income	-175.77M	PEG	-	EPS next Q	-0.89	Inst Own	42.36%	Short Float	6.59%	Perf Quarter	223.98%
Sales	202.57M	P/S	1.42	EPS this Y	47.11%	Inst Trans	-11.90%	Short Ratio	5.25	Perf Half Y	265.68%
Book/sh	8.78	P/B	1.26	EPS next Y	48.27%	ROA	-34.50%	Short Interest	1.07M	Perf Year	17.48%
Cash/sh	5.00	P/C	2.22	EPS next 5Y	-	ROE	-72.97%	52W Range	1.16 - 12.57	Perf YTD	302.91%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-51.15%	52W High	-11.85%	Beta	2.62
Dividend TTM	-	Quick Ratio	2.95	Sales past 5Y	5.08%	Gross Margin	29.93%	52W Low	855.17%	ATR (14)	1.02
Dividend Ex-Date	-	Current Ratio	3.10	EPS Y/Y TTM	85.48%	Oper. Margin	-80.80%	RSI (14)	58.05	Volatility	11.21% 10.14%
Employees	1000	Debt/Eq	0.53	Sales Y/Y TTM	-13.69%	Profit Margin	-86.77%	Recom	2.00	Target Price	11.38
Option/Short	Yes / Yes	LT Debt/Eq	0.51	EPS Q/Q	96.22%	Payout	-	Rel Volume	0.73	Prev Close	11.17
Sales Surprise	7.11%	EPS Surprise	24.87%	Sales Q/Q	-6.41%	Earnings	Apr 29 AMC	Avg Volume	203.48K	Price	11.08
SMA20	9.21%	SMA50	22.52%	SMA200	118.01%	Trades		Volume	148,884	Change	-0.81%

Apr-23-24 08:30AM	GeneDx Announces Partnership with Komodo Health to Expand Access to World's Largest Rare Disease Dataset (GlobeNewswire) +15.50%
Apr-04-24 04:05PM	GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024 (GlobeNewswire)
Mar-21-24 09:55AM	Here's Why GENEDX HOLDINGS (WGS) Could be Great Choice for a Bottom Fisher (Zacks) +7.87%
Mar-14-24 08:30AM	GeneDx to Present Data at the 2024 American College of Medical Genetics (ACMG) Annual Meeting Demonstrating Clinical Superiority of its Exome, Paving the Way for the Future of Genomics (GlobeNewswire)
Feb-26-24 04:05PM	GeneDx to Participate in 44th Annual Cowen Health Care Conference (GlobeNewswire)
08:33AM	Loading…
Feb-21-24 08:33AM	GeneDx Holdings Corp. (NASDAQ:WGS) Q4 2023 Earnings Call Transcript (Insider Monkey) +32.63%
Feb-20-24 04:26PM	GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024 (GlobeNewswire)
Feb-01-24 04:30PM	GeneDx to Report Fourth Quarter 2023 Financial Results on Tuesday, February 20, 2024 (GlobeNewswire)
Jan-24-24 04:30PM	GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-08-24 08:55AM	GeneDx Announces Preliminary 2023 Financial Results (GlobeNewswire) +40.36%
Dec-01-23 08:30AM	GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy (GlobeNewswire)
Nov-28-23 04:05PM	GeneDx to Participate in 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) +12.80%
Nov-20-23 04:05PM	GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -13.13%
Nov-10-23 09:55AM	Bears are Losing Control Over GeneDx Holdings Corp. (WGS), Here's Why It's a 'Buy' Now (Zacks) -13.61%
Nov-05-23 12:10PM	GeneDx Holdings Corp. (NASDAQ:WGS) Q3 2023 Earnings Call Transcript (Insider Monkey)
08:19AM	Loading…
Oct-31-23 08:19AM	Q3 2023 GeneDx Holdings Corp Earnings Call (Thomson Reuters StreetEvents) -30.34%
Oct-30-23 06:02PM	GeneDx Holdings Corp (WGS) Reports Q3 2023 Financial Results (GuruFocus.com) -8.56%
04:05PM	GeneDx Reports Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Oct-09-23 04:05PM	GeneDx to Report Third Quarter 2023 Financial Results on Monday, October 30, 2023 (GlobeNewswire)
Sep-22-23 04:05PM	GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-13-23 01:01PM	Insider Sell: CEO Katherine Stueland Sells 2,675 Shares of GeneDx Holdings Corp (GuruFocus.com) -5.03%
Sep-11-23 08:00AM	GeneDx Announces Evolution of Executive Leadership Team (GlobeNewswire)
Sep-06-23 08:00AM	GeneDx Announces Industry-Leading Accomplishment of 500,000 Clinical Exomes Sequenced (GlobeNewswire)
Aug-21-23 07:00AM	GeneDx Announces Data Demonstrating that Whole Exome and Genome Sequencing Report Fewer Variants of Uncertain Significance (VUS) than Multi-Gene Panel Testing Published in Genetics in Medicine (GlobeNewswire)
Aug-09-23 08:16AM	PacBio (PACB) Inks Research Collaboration for Genome Sequencing (Zacks) -12.63%
07:59AM	Q2 2023 GeneDx Holdings Corp Earnings Call (Thomson Reuters StreetEvents)
Aug-08-23 08:05PM	GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:05PM	GeneDx Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Aug-07-23 08:00AM	PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care (GlobeNewswire) -6.30%
Jul-19-23 07:05AM	GeneDx and Prognos Health Announce Strategic Partnership to Help Rare Disease Patients More Rapidly Gain Access to Potential Treatment Options (GlobeNewswire) +6.48%
04:05PM	Loading…
Jul-18-23 04:05PM	GeneDx to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023 (GlobeNewswire)
Jun-28-23 07:00AM	GeneDx to Present New Data on Urine Mitochondrial DNA Testing at the 2023 United Mitochondrial Disease Foundations Mitochondrial Medicine Symposium (GlobeNewswire) +11.53%
Jun-26-23 04:01PM	GeneDx Announces New Tool to Help Harness Human Pangenome Diversity for Clinical Interpretation of Variants (GlobeNewswire)
Jun-20-23 07:00AM	GeneDx Commends the States of Arizona and Florida for Adding Rapid Whole Genome Sequencing (rWGS) as a Covered Benefit for Medicaid Pediatric Patients (GlobeNewswire) -6.11%
May-24-23 04:05PM	GeneDx to Participate in Upcoming Investor Conferences in June (GlobeNewswire)
May-23-23 07:00AM	GeneDx to Participate in World Orphan Drug Congress Keynote and Panel Presentations (GlobeNewswire)
May-22-23 04:05PM	GeneDx Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) +13.10%
May-15-23 09:35AM	Down -27.82% in 4 Weeks, Here's Why You Should You Buy the Dip in GeneDx Holdings Corp. (WGS) (Zacks)
May-09-23 04:05PM	GeneDx Reports First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire) -5.65%
May-04-23 07:00AM	GeneDx Adds Buccal Swab as Non-Invasive Whole Genome Sequencing Sample Collection Option (GlobeNewswire)
May-03-23 01:06PM	GeneDx Announces Clarification Regarding CUSIP Number for Public Warrant Holders (GlobeNewswire)
Apr-28-23 06:39PM	Why GeneDx Holdings Stock Lagged the Market Today (Motley Fool)
08:10AM	GeneDx Announces Reverse Stock Split (GlobeNewswire)
07:04AM	Daily Vickers Top Buyers & Sellers for 04/28/2023 (Argus Research)
Apr-18-23 04:05PM	GeneDx to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023 (GlobeNewswire)
12:55PM	Shareholders Should Be Pleased With GeneDx Holdings Corp.'s (NASDAQ:WGS) Price (Simply Wall St.)
Apr-03-23 08:30AM	GeneDx Appoints Devin K. Schaffer, J.D., M.B.A, as General Counsel (GlobeNewswire)
Mar-22-23 04:36PM	Why Shares of GeneDx Dropped Wednesday (Motley Fool) -16.02%
Mar-20-23 09:07PM	GeneDx Holdings Corp. (NASDAQ:WGS) Q4 2022 Earnings Call Transcript (Insider Monkey) +41.30%
08:45AM	GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease Diagnostic Odyssey (GlobeNewswire)
Mar-18-23 06:48PM	The 7 Worst Stocks to Buy Now (InvestorPlace)
Mar-16-23 08:45AM	GeneDx Presents New Data at ACMG Demonstrating the Benefits of Exome Sequencing Over Chromosomal Microarray (GlobeNewswire)
Mar-14-23 04:16PM	GeneDx Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (GlobeNewswire)
Mar-01-23 07:30AM	GeneDx to Participate in the Cowen 43rd Annual Healthcare Conference (GlobeNewswire) -5.20%
Feb-28-23 08:30AM	GeneDx honors Rare Disease Day and announces presentations and research at the 2023 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting (GlobeNewswire)
Feb-21-23 04:30PM	GeneDx to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14th, 2023 (GlobeNewswire) -8.42%
Feb-16-23 08:30AM	GeneDx Rare Disease Data Demonstrates Utility in Drug Candidate Identification for Common Diseases (GlobeNewswire) +5.82%
Jan-31-23 04:15PM	GeneDx Announces Closing of Underwritten Public Offering and Concurrent Registered Direct Offering (GlobeNewswire) +5.75%
Jan-30-23 08:30AM	GeneDx Makes Significant Industry-Wide Contributions to New Disease Gene Discovery (GlobeNewswire)
Jan-27-23 06:00AM	GeneDx Holdings Announces Pricing Of A $150 Million Underwritten Public Offering Of Class A Common Stock And Concurrent Registered Direct Offering (GlobeNewswire) +10.26%
Jan-26-23 04:53PM	GeneDx Announces Proposed Underwritten Public Offering of Class a Common Stock and Concurrent Registered Direct Offering (GlobeNewswire)

GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Stueland Katherine	CHIEF EXECUTIVE OFFICER	Mar 18 '24	Sale	10.59	8,559	90,661	66,698	Mar 19 04:15 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 18 '24	Sale	10.59	3,253	34,455	28,927	Mar 19 04:14 PM
Saad Kareem	CHIEF TRANSFORMATION OFFICER	Mar 18 '24	Sale	10.59	2,008	21,269	29,517	Mar 19 04:14 PM
Stueland Katherine	CHIEF EXECUTIVE OFFICER	Mar 16 '24	Option Exercise	0.00	18,750	0	75,257	Mar 19 04:15 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 16 '24	Option Exercise	0.00	7,197	0	32,180	Mar 19 04:14 PM
Saad Kareem	CHIEF TRANSFORMATION OFFICER	Mar 16 '24	Option Exercise	0.00	5,114	0	31,525	Mar 19 04:14 PM
Stueland Katherine	CHIEF EXECUTIVE OFFICER	Mar 12 '24	Sale	9.21	2,618	24,111	56,507	Mar 13 04:24 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 12 '24	Sale	9.21	931	8,574	24,983	Mar 13 04:28 PM
Saad Kareem	CHIEF TRANSFORMATION OFFICER	Mar 12 '24	Sale	9.21	897	8,261	26,411	Mar 13 04:22 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 09 '24	Option Exercise	0.00	2,462	0	25,914	Mar 12 05:27 PM
Stueland Katherine	CHIEF EXECUTIVE OFFICER	Mar 09 '24	Option Exercise	0.00	6,547	0	59,125	Mar 12 05:26 PM
Saad Kareem	CHIEF TRANSFORMATION OFFICER	Mar 09 '24	Option Exercise	0.00	2,841	0	27,308	Mar 12 05:25 PM
Casdin Capital, LLC	Director	Mar 05 '24	Buy	8.83	900	7,944	2,703,509	Mar 06 07:32 PM
Casdin Capital, LLC	Director	Mar 04 '24	Buy	8.74	40,000	349,708	2,702,609	Mar 06 07:32 PM
Saad Kareem	CHIEF TRANSFORMATION OFFICER	Jan 22 '24	Sale	3.24	193	625	24,467	Jan 23 04:10 PM
Saad Kareem	CHIEF TRANSFORMATION OFFICER	Jan 19 '24	Option Exercise	0.00	546	0	24,660	Jan 23 04:10 PM
Saad Kareem	Chief Transformation Officer	Jan 03 '24	Sale	2.58	105	271	24,114	Jan 04 05:03 PM
Saad Kareem	Chief Transformation Officer	Jan 01 '24	Option Exercise	0.00	273	0	24,219	Jan 03 04:25 PM
Ryan Jason	Executive Chairman	Dec 31 '23	Option Exercise	0.00	67,780	0	73,614	Jan 03 04:23 PM
Stueland Katherine	Chief Executive Officer	Dec 18 '23	Sale	2.16	11,734	25,338	52,578	Dec 19 09:26 PM
Feeley Kevin	Chief Financial Officer	Dec 18 '23	Sale	2.16	2,948	6,366	23,035	Dec 19 09:24 PM
Saad Kareem	Chief Transformation Officer	Dec 18 '23	Sale	2.16	1,700	3,671	23,946	Dec 19 09:25 PM
Stueland Katherine	Chief Executive Officer	Dec 16 '23	Option Exercise	0.00	18,750	0	64,312	Dec 19 09:26 PM
Saad Kareem	Chief Transformation Officer	Dec 16 '23	Option Exercise	0.00	5,114	0	25,646	Dec 19 09:25 PM
Feeley Kevin	Chief Financial Officer	Dec 16 '23	Option Exercise	0.00	7,197	0	25,983	Dec 19 09:24 PM
Stueland Katherine	Chief Executive Officer	Dec 11 '23	Sale	1.61	3,673	5,915	45,562	Dec 12 04:06 PM
Feeley Kevin	Chief Financial Officer	Dec 11 '23	Sale	1.61	908	1,462	18,786	Dec 12 04:04 PM
Saad Kareem	Chief Transformation Officer	Dec 11 '23	Sale	1.61	850	1,369	20,532	Dec 12 04:05 PM
Saad Kareem	Chief Transformation Officer	Dec 09 '23	Option Exercise	0.00	2,841	0	21,382	Dec 12 04:05 PM
Stueland Katherine	Chief Executive Officer	Dec 09 '23	Option Exercise	0.00	6,546	0	49,235	Dec 12 04:06 PM
Feeley Kevin	Chief Financial Officer	Dec 09 '23	Option Exercise	0.00	2,462	0	19,694	Dec 12 04:04 PM
Feeley Kevin	Chief Financial Officer	Dec 04 '23	Sale	1.77	270	478	17,232	Dec 05 04:45 PM
Ryan Jason	Executive Chairman	Nov 17 '23	Buy	1.54	58,000	89,181	114,742	Nov 20 04:32 PM
Ryan Jason	Executive Chairman	Nov 16 '23	Buy	1.27	56,742	72,187	56,742	Nov 20 04:32 PM
Meister Keith A.	Director	Nov 15 '23	Sale	1.29	883,742	1,140,027	3,011,066	Nov 17 04:18 PM
PFENNIGER RICHARD C JR	Director	Nov 08 '23	Buy	1.49	10,000	14,889	20,918	Nov 08 07:19 PM
Saad Kareem	Chief Transformation Officer	Oct 20 '23	Sale	3.44	164	564	18,541	Oct 23 05:52 PM
Ryan Jason	Executive Chairman	Oct 17 '23	Sale	3.19	42	134	5,834	Oct 18 04:59 PM
Saad Kareem	Chief Transformation Officer	Oct 03 '23	Sale	3.56	85	303	18,159	Oct 03 04:19 PM
Stueland Katherine	Chief Executive Officer	Sep 18 '23	Sale	4.16	10,752	44,749	42,689	Sep 19 06:09 PM
Feeley Kevin	Chief Financial Officer	Sep 18 '23	Sale	4.16	2,742	11,409	16,785	Sep 19 06:08 PM
Saad Kareem	Chief Transformation Officer	Sep 18 '23	Sale	4.16	1,580	6,575	17,971	Sep 19 06:08 PM
Feeley Kevin	Chief Financial Officer	Sep 16 '23	Option Exercise	0.00	7,197	0	19,527	Sep 19 06:08 PM
Stueland Katherine	Chief Executive Officer	Sep 11 '23	Sale	4.62	2,675	12,369	34,691	Sep 12 06:42 PM
Feeley Kevin	Chief Financial Officer	Sep 11 '23	Sale	4.62	904	4,180	12,330	Sep 12 06:40 PM
Saad Kareem	Chief Transformation Officer	Sep 11 '23	Sale	4.62	846	3,912	14,437	Sep 12 06:41 PM
Feeley Kevin	Chief Financial Officer	Sep 09 '23	Option Exercise	0.00	2,462	0	13,234	Sep 12 06:40 PM
Feeley Kevin	Chief Financial Officer	Sep 05 '23	Sale	4.38	269	1,178	10,772	Sep 06 04:56 PM
PFENNIGER RICHARD C JR	Director	Aug 17 '23	Buy	5.10	5,000	25,523	10,918	Aug 18 05:10 PM
White Karen Ann	Chief People Officer	Jul 26 '23	Sale	7.41	61	452	4,761	Jul 27 04:12 PM
Saad Kareem	Chief Transformation Officer	Jul 20 '23	Sale	7.85	163	1,280	12,442	Jul 21 09:58 PM
Saad Kareem	Chief Transformation Officer	Jul 03 '23	Sale	5.99	83	497	12,059	Jul 05 05:16 PM
White Karen Ann	Chief People Officer	Jul 03 '23	Sale	5.99	45	270	4,685	Jul 05 05:18 PM
Stueland Katherine	Chief Executive Officer	Jun 20 '23	Sale	6.37	7,965	50,727	30,819	Jun 21 04:05 PM
Feeley Kevin	Chief Financial Officer	Jun 20 '23	Sale	6.37	2,744	17,473	10,324	Jun 21 04:06 PM
White Karen Ann	Chief People Officer	Jun 20 '23	Sale	6.37	1,549	9,865	4,631	Jun 21 04:05 PM
Saad Kareem	Chief Transformation Officer	Jun 20 '23	Sale	6.37	1,221	7,774	11,869	Jun 21 04:04 PM
Feeley Kevin	Chief Financial Officer	Jun 16 '23	Option Exercise	0.00	7,197	0	13,068	Jun 21 04:06 PM
Feeley Kevin	Chief Financial Officer	Jun 13 '23	Sale	6.49	903	5,860	5,871	Jun 13 05:19 PM
Stueland Katherine	Chief Executive Officer	Jun 12 '23	Sale	6.49	2,674	17,354	20,034	Jun 13 05:23 PM
Saad Kareem	Chief Transformation Officer	Jun 12 '23	Sale	6.49	845	5,484	7,976	Jun 13 05:22 PM
White Karen Ann	Chief People Officer	Jun 12 '23	Sale	6.49	828	5,374	2,770	Jun 13 05:25 PM
Feeley Kevin	Chief Financial Officer	Jun 09 '23	Option Exercise	0.00	2,462	0	6,774	Jun 13 05:19 PM
Feeley Kevin	Chief Financial Officer	Jun 02 '23	Sale	7.00	263	1,841	4,312	Jun 05 04:42 PM
PFENNIGER RICHARD C JR	Director	May 18 '23	Buy	5.90	5,000	29,500	5,918	May 22 04:59 PM
Stueland Katherine	Chief Executive Officer	May 16 '23	Sale	6.50	8,685	56,439	16,162	May 18 07:21 PM
Feeley Kevin	Chief Financial Officer	May 16 '23	Sale	6.50	1,516	9,852	3,856	May 18 07:22 PM
Sherman Rachel E.	Director	May 02 '23	Option Exercise	0.00	45,454	0	58,290	May 04 04:15 PM
Casdin Eli	Director	May 02 '23	Option Exercise	0.00	45,454	0	58,290	May 04 04:04 PM
Leproust Emily M.	Director	May 02 '23	Option Exercise	0.00	45,454	0	83,290	May 04 04:07 PM
RUCH JOSHUA	Director	May 02 '23	Option Exercise	0.00	45,454	0	62,568	May 04 04:14 PM
PFENNIGER RICHARD C JR	Director	May 02 '23	Option Exercise	0.00	30,303	0	30,303	May 04 04:11 PM
Meister Keith A.	Director	May 02 '23	Option Exercise	0.00	45,454	0	45,454	May 04 04:09 PM
Feeley Kevin	Chief Financial Officer	Apr 29 '23	Option Exercise	0.00	99,432	0	177,292	May 02 08:32 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

WGS

GeneDx Holdings Corp

Upgrade your FINVIZ experience